---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-009203"
form_type: "8-K/A"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T06:16:08.805494+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Windtree signs sourcing deal for Evofem's FDA-approved PHEXXI contraceptive gel

## Summary
- License and Supply Agreement makes Windtree sourcing partner for Evofem's PHEXXI (hormone-free vaginal gel).
- PHEXXI generated >$19M revenue in FY2024; 96,000 boxes of 12 applicators sold.
- Windtree aims to cut manufacturing costs via its contacts, aiding Evofem's global expansion.
- Saundra Pelletier is CEO of Evofem and also serves on Windtree's board of directors.
- Deal is first step in Windtree's new strategy to become a revenue-generating biotech.

## SEC filing metadata
- accession: 0001437749-25-009203
- form_type: 8-K/A
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774925009203/0001437749-25-009203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774925009203/wint20250324_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-009203
- JSON: https://secwatch.observer/filing/0001437749-25-009203.json
- Plain text: https://secwatch.observer/filing/0001437749-25-009203.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.